Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy

Serkan Ademoğlu; Ferudun Kaya; İsa Caner Aydın; Ahmet Orhan Sunar

doi:10.38053/acmj.1967270

Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy

Abstract

Aims: This study evaluated the association of preoperative carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels at diagnosis with pathological aggressiveness and local recurrence in patients with gastric cancer undergoing gastrectomy. Methods: This retrospective single-center study included 58 patients who underwent subtotal or total gastrectomy and had available preoperative tumor markers. CEA >5 ng/ml and CA19-9 >37 U/ml were considered elevated. Clinicopathological data, recurrence patterns, disease-free survival (DFS) events, and overall survival were analyzed. Results: Elevated CEA and CA19-9 were detected in 17 (29.31%) and 12 (20.69%) patients, respectively. At least one marker was elevated in 24 patients (41.38%), and both markers were elevated in 5 (8.62%). During follow-up, local recurrence occurred in 7 patients (12.07%), peritoneal recurrence in 16 (27.59%), distant metastasis in 9 (15.52%), and DFS events in 21 (36.21%). Local recurrence was not significantly associated with tumor marker status. However, patients with DFS events had higher CEA and CA19-9 levels (p=0.029 and p=0.006). Elevation of either marker was associated with DFS events (p=0.026), while concomitant elevation was associated with N3 disease and advanced pathological stage. Conclusion: In this limited cohort, preoperative CEA and CA19-9 levels were not significantly associated with local recurrence, but they may reflect tumor burden, nodal involvement, and risk of DFS events after gastrectomy.

Keywords

Ethical Statement

This study was approved by the Gaziantep City Hospital Non-Interventional Clinical Research Ethics Committee (Decision No: 519/2026; Date: 27 March 2026). The study was conducted in accordance with the principles of the Declaration of Helsinki.

References

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005-1020. doi:10.1016/j.annonc.2022.07.004
Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167-192. doi:10.6004/jnccn.2022.0008
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1-25. doi:10.1007/s10120-022-01331-8
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1
Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:397. doi:10.1186/1477-7819-12-397
Tang XH, Wu XL, Gan XJ, et al. Using normalized carcinoembryonic antigen and carbohydrate antigen 19 to predict and monitor the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer. Int J Mol Sci. 2023;24(15):12192. doi:10.3390/ijms241512192
Shibata C, Nakano T, Yasumoto A, et al. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer. BMC Surg. 2022;22(1):213. doi:10.1186/s12893-022-01667-z

Ma X, Zhou X, Guo J, et al. CA19-9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy. BMC Surg. 2024;24(1):31. doi:10.1186/s12893-024-02324-3
Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6(3):142-145. doi:10.1007/s10120-003-0240-9
Choi SR, Jang JS, Lee JH, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci. 2006;51(11):2081-2086. doi:10.1007/s10620-006-9166-5
Moriyama J, Oshima Y, Nanami T, et al. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Surg Today. 2021;51(10):1638-1648. doi:10.1007/s00595-021-02248-y
Deng K, Yang L, Hu B, Wu H, Zhu H, Tang C. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One. 2015;10(4):e0124151. doi:10.1371/journal.pone.0124151
Song YX, Huang XZ, Gao P, et al. Clinicopathologic and prognostic value of serum carbohydrate antigen 19-9 in gastric cancer: a meta-analysis. Dis Markers. 2015;2015:549843. doi:10.1155/2015/549843
Dilege E, Mihmanli M, Demir U, et al. Prognostic value of preoperative CEA and CA19-9 levels in resectable gastric cancer. Hepatogastroenterology. 2010;57(99-100):674-677.
Duraker N, Celik AN. The prognostic significance of preoperative serum CA19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76(4):266-271. doi:10.1002/jso.1044
Ikeda Y, Oomori H, Koyanagi N, et al. Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncology. 1995;52(6):483-486. doi:10.1159/000227515
Xu DZ, Geng QR, Long ZJ, et al. Positive lymph node ratio is an independent prognostic factor in gastric cancer after D2 resection regardless of the examined number of lymph nodes. Ann Surg Oncol. 2009;16(2):319-326. doi:10.1245/s10434-008-0240-4

Details

Primary Language

English

Subjects

Gastroenterology Surgery

Journal Section

Research Article

Authors

Serkan Ademoğlu ^*
0000-0003-2595-0064
Türkiye

Ferudun Kaya
0009-0000-6037-7801
Türkiye

İsa Caner Aydın
0000-0003-2434-0045
Türkiye

Ahmet Orhan Sunar
0000-0001-5564-6923
Türkiye

Publication Date

September 11, 2026

Submission Date

June 9, 2026

Acceptance Date

July 18, 2026

Published in Issue

Year 2026 Volume: 8 Number: 5

DOI

https://doi.org/10.38053/acmj.1967270

IZ

https://izlik.org/JA85ZE72FJ

Cite

RIS / Bibtex

APA

Ademoğlu, S., Kaya, F., Aydın, İ. C., & Sunar, A. O. (2026). Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy. Anatolian Current Medical Journal, 8(5), 869-875. https://doi.org/10.38053/acmj.1967270

AMA

1.Ademoğlu S, Kaya F, Aydın İC, Sunar AO. Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy. Anatolian Curr Med J / ACMJ / acmj. 2026;8(5):869-875. doi:10.38053/acmj.1967270

Chicago

Ademoğlu, Serkan, Ferudun Kaya, İsa Caner Aydın, and Ahmet Orhan Sunar. 2026. “Preoperative Tumor Markers, Pathological Aggressiveness, and Local Recurrence in Gastric Cancer After Gastrectomy”. Anatolian Current Medical Journal 8 (5): 869-75. https://doi.org/10.38053/acmj.1967270.

EndNote

Ademoğlu S, Kaya F, Aydın İC, Sunar AO (September 1, 2026) Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy. Anatolian Current Medical Journal 8 5 869–875.

IEEE

[1]S. Ademoğlu, F. Kaya, İ. C. Aydın, and A. O. Sunar, “Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy”, Anatolian Curr Med J / ACMJ / acmj, vol. 8, no. 5, pp. 869–875, Sept. 2026, doi: 10.38053/acmj.1967270.

ISNAD

Ademoğlu, Serkan - Kaya, Ferudun - Aydın, İsa Caner - Sunar, Ahmet Orhan. “Preoperative Tumor Markers, Pathological Aggressiveness, and Local Recurrence in Gastric Cancer After Gastrectomy”. Anatolian Current Medical Journal 8/5 (September 1, 2026): 869-875. https://doi.org/10.38053/acmj.1967270.

JAMA

1.Ademoğlu S, Kaya F, Aydın İC, Sunar AO. Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy. Anatolian Curr Med J / ACMJ / acmj. 2026;8:869–875.

MLA

Ademoğlu, Serkan, et al. “Preoperative Tumor Markers, Pathological Aggressiveness, and Local Recurrence in Gastric Cancer After Gastrectomy”. Anatolian Current Medical Journal, vol. 8, no. 5, Sept. 2026, pp. 869-75, doi:10.38053/acmj.1967270.

Vancouver

1.Serkan Ademoğlu, Ferudun Kaya, İsa Caner Aydın, Ahmet Orhan Sunar. Preoperative tumor markers, pathological aggressiveness, and local recurrence in gastric cancer after gastrectomy. Anatolian Curr Med J / ACMJ / acmj. 2026 Sep. 1;8(5):869-75. doi:10.38053/acmj.1967270